ANI Pharmaceuticals
ANIP | NASDAQ
$70.89
-$0.55 (-0.77%)
At close: Nov 16, 2026, 4:00 PM ET
$70.84
-$0.05 (-0.07%)
After-hours:
Nov 16, 2026, 7:30 PM ET
ANI Pharmaceuticals Company Profile
Company profile explainedCompany Profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Key Executives
| Name | Position |
|---|---|
| Nikhil Lalwani | President, Chief Executive Officer & Director |
| Stephen Carey | Senior Vice President of Finance & Chief Financial Officer |
| Chad Gassert | Senior Vice President of Corporate Development & Strategy |
| Christopher K. Mutz | Senior Vice President & Head of Rare Disease |
| Elizabeth Powell | Chief Compliance Officer & Head of Legal of Rare Disease |
| Irina Rivkind Koffler | Vice President of Investor Relations |
| Krista L. Davis | Senior Vice President & Chief Human Resources Officer |
| Meredith W. Cook | Senior Vice President, General Counsel & Corporate Secretary |
| Muthusamy Shanmugam | Head of R&D and COO of New Jersey Operations |
| Ori Gutwerg | Senior Vice President of Generics |
ANI Pharmaceuticals
| Country | United States |
| IPO Date | May 5, 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 970 |
| CEO | Nikhil Lalwani |
Contact Details
210 Main Street West Baudette,
Minnesota 56623 United States
Stock Details
| Ticker Symbol | ANIP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001023024 |
| CUSIP Number | 00182C103 |
| ISIN Number | US00182C1036 |
| SIC Code | 2834 |
Recent News
- 10 days ago / seekingalpha.comANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript
- 12 days ago / marketbeat.comANI Pharmaceuticals Q3 Earnings Call Highlights
- 12 days ago / zacks.comANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
- 12 days ago / zacks.comANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
- 12 days ago / globenewswire.comANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
- 12 days ago / globenewswire.comREPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
- 12 days ago / globenewswire.comANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
- 14 days ago / globenewswire.comANI Pharmaceuticals to Present at Upcoming November Investor Conferences
- 25 days ago / globenewswire.comANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
- 29 days ago / globenewswire.comANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
Add to Watchlist
Select watchlists to add or remove ANIP